Clinical Trials for Mesothelioma Patients—A Study to Find the Best Dose of SU011248

Read about a current clinical trial about the use of SU011248 for patients with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.

A Study to Find the Best Dose of SU011248 When Given With Pemetrexed, Pemetrexed and Cisplatin or Pemetrexed and Carboplatin in Patients with Advanced Solid Tumors

Purpose

This study will assess the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with pemetrexed, pemetrexed and cisplatin or pemetrexed and carboplatin in patients with advanced solid tumors.

Phase, Condition and Intervention:

Phase I; Non-Small Cell Lung Cancer, Mesothelioma, Neoplasms; Drug: Sunitinib, Pemetrexed, Cisplatin, Carboplatin

Study Type and Design:

Interventional; Treatment, Non-Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study

Official Title:

Phase I Study of SU011248 in Combination with Pemetrexed, Pemetrexed/Cisplatin and Pemetrexed/Carboplatin in Patients with Advanced Solid Malignancies

Courtesy of ClinicalTrials.gov, a service of the U.S. National Institutes of Health

If you or a loved one has been diagnosed with an Asbestos illness like mesothelioma, lung cancer or asbestosis, complete the form on this page to get a FREE and prompt review of your case by a leading Asbestos attorney. Weitz & Luxenberg is a leading mesothelioma law firm with a substantial history of success in asbestos exposure cases.